SCF Antibody [K20P17] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:10000 IHC1:100-1:250 IF1:100 - 1:500 FCM1:20 - 1:50

Application
WB, IHC, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
30 kDa 18 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
SCF Antibody [K20P17] detects endogenous levels of total SCF protein.

Clone
K20P17

Synonym(s)
MGF; SCF; KITLG; Kit ligand; Mast cell growth factor; Stem cell factor; c-Kit ligand

Background
Stem Cell Factor (SCF/KITLG), a glycoprotein growth factor, binds to the c-KIT receptor tyrosine kinase to initiate hematopoietic stem cell (HSC) maintenance, mast cell development, and primordial germ cell survival by forming SCF/c-KIT dimers that autophosphorylate receptor juxtamembrane and kinase domains, activating PI3K/AKT (for cell survival), MAPK/ERK (for proliferation), and PLCγ (for calcium mobilization) pathways that converge on gene expression changes essential for stemness and lineage commitment. SCF features a compact four-α-helical bundle with site 2 and 3 interfaces (Asp25, Leu43, Phe60) mediating high-affinity dimeric c-KIT binding, and exists as both a membrane-bound (full-length) or soluble (proteolytically cleaved) form with distinct signaling kinetics. SCF maintains HSCs in the bone marrow niche via stromal cell presentation, synergizes with TPO and FLt3L for megakaryocyte and erythroid progenitor support, drives mast cell survival, proliferation, and degranulation via KIT D816V signaling, supports melanocyte migration during development, and promotes primordial germ cell survival and migration to the gonadal ridges. The SCF/c-KIT axis forms the core hematopoietic niche signaling pathway and is a key regulator of gametogenesis; pathologically, gain-of-function KIT mutations (such as D816V and N822K) with autocrine SCF drive systemic mastocytosis, gastrointestinal stromal tumors (GIST), and acute myeloid leukemia, while therapeutic KIT inhibitors specifically target mutant-driven oncogenesis without broadly disrupting wild-type hematopoiesis.

Background

Stem Cell Factor (SCF/KITLG), a glycoprotein growth factor, binds to the c-KIT receptor tyrosine kinase to initiate hematopoietic stem cell (HSC) maintenance, mast cell development, and primordial germ cell survival by forming SCF/c-KIT dimers that autophosphorylate receptor juxtamembrane and kinase domains, activating PI3K/AKT (for cell survival), MAPK/ERK (for proliferation), and PLCγ (for calcium mobilization) pathways that converge on gene expression changes essential for stemness and lineage commitment. SCF features a compact four-α-helical bundle with site 2 and 3 interfaces (Asp25, Leu43, Phe60) mediating high-affinity dimeric c-KIT binding, and exists as both a membrane-bound (full-length) or soluble (proteolytically cleaved) form with distinct signaling kinetics. SCF maintains HSCs in the bone marrow niche via stromal cell presentation, synergizes with TPO and FLt3L for megakaryocyte and erythroid progenitor support, drives mast cell survival, proliferation, and degranulation via KIT D816V signaling, supports melanocyte migration during development, and promotes primordial germ cell survival and migration to the gonadal ridges. The SCF/c-KIT axis forms the core hematopoietic niche signaling pathway and is a key regulator of gametogenesis; pathologically, gain-of-function KIT mutations (such as D816V and N822K) with autocrine SCF drive systemic mastocytosis, gastrointestinal stromal tumors (GIST), and acute myeloid leukemia, while therapeutic KIT inhibitors specifically target mutant-driven oncogenesis without broadly disrupting wild-type hematopoiesis.

References
https://pubmed.ncbi.nlm.nih.gov/10582338/ https://pubmed.ncbi.nlm.nih.gov/17255936/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%